Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine and Rosuvastatin for COVID-19 Complications
NCT04472611Phase 3Completed
- Sponsor
- Yale University
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing SOC + Colchicine + Rosuvastatin with Standard of Care (2 arms). Primary endpoint: Number of Participants With COVID-19 Severity at 30 days. Started Oct 2020; status: completed.
02
Drugs
colchicinerosuvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04472611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472611.